Michael Siluk | UCG | Common Photos Group | Getty Photos
Novo Nordisk rose as a lot as 4% after England’s drug value watchdog advisable the usage of its best-selling drug Wegovy to forestall coronary heart assaults and strokes, marking the primary GLP-1 backed for this use within the nation.
Wegovy is principally a weight reduction therapy however it’s also authorised for lowering the chance of main cardiovascular occasions in individuals dwelling with obese or weight problems.
The brand new advice the Nationwide Institute for Well being and Care Excellence (NICE), England’s drug value regulator, will considerably increase entry to Wegovy on the nation’s Nationwide Well being Service (NHS).
Round 1.2 million individuals might use the drugs to assist defend them towards having additional coronary heart assaults or strokes, as it’s made obtainable for this situation, NICE mentioned in an announcement on Wednesday.
The regulator, which assesses a drugs’s cost-effectiveness, advisable semaglutide, the lively ingredient in Wegovy and diabetes therapy Ozempic, as an possibility for adults who’ve beforehand had a coronary heart assault, a stroke, or a critical circulation drawback within the legs and who’ve a physique mass index (BMI) of at the least 27.
Novo’s Copenhagen-listed shares have been final seen up 1.7% in morning buying and selling, paring some earlier good points. The pan-European blue-chip index Stoxx 600 was up 1.8%.
Scientific trials have proven that sufferers taking a 2.4 mg dose of semaglutide alongside present cardiovascular medicines have been 20% much less more likely to have a critical cardiovascular occasion in comparison with placebo.
Wegovy secured UK approval in 2024 for lowering the chance of main heart problems in individuals dwelling with obese or weight problems and coronary heart illness, however entry to the drugs was restricted to sufferers paying out-of-pocket if used to deal with these circumstances.
Novo Nordisk has confronted a number of setbacks over the previous yr because it has misplaced market share to U.S.-based rival Eli Lilly, whose medicines have resulted in additional pronounced weight reduction at authorised doses. Additionally it is going through important pricing stress amid political stress in its largest market, the U.S., to decrease the prices of prescribed drugs, in addition to publicity to generic competitors in India and different markets this yr.
To date in 2026, Novo has launched Wegovy in a capsule as the primary oral GLP-1 for weight reduction, and higher-dose Wegovy that’s extra on par with Lilly’s rival Zepbound, because it’s making an attempt to claw again market share.
Coronary heart and circulatory illness is among the main causes of early dying and unwell well being in England, and about 1 in 4 adults within the U.Ok. is estimated to dwell with weight problems, in accordance with the NHS.
Wegovy will probably be integrated for treating heart problems and alongside NICE’s present steering recommending semaglutide for weight administration in adults dwelling with weight problems or obese.
“Collectively, these choices mirror the rising physique of proof that this class of medicines gives advantages extending past weight reduction,” NICE mentioned.
“Right this moment’s NICE advice for Wegovy is a vital step ahead for individuals dwelling with established heart problems and obese or weight problems,” mentioned Sebnem Avsar Tuna, basic supervisor at Novo Nordisk U.Ok.
“It means clinicians in England now have entry to an additional therapy that NICE has discovered to be value efficient, the primary and solely GLP 1 receptor agonist confirmed to cut back the chance of coronary heart assault, stroke or cardiovascular dying on this excessive danger inhabitants.”
